PL3593139T3 - Biomarkery nowotworowe - Google Patents
Biomarkery nowotworoweInfo
- Publication number
- PL3593139T3 PL3593139T3 PL18710027.6T PL18710027T PL3593139T3 PL 3593139 T3 PL3593139 T3 PL 3593139T3 PL 18710027 T PL18710027 T PL 18710027T PL 3593139 T3 PL3593139 T3 PL 3593139T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer biomarkers
- biomarkers
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0041—Detection of breast cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1703641.9A GB201703641D0 (en) | 2017-03-07 | 2017-03-07 | Cancer biomarkers |
| GBGB1703640.1A GB201703640D0 (en) | 2017-03-07 | 2017-03-07 | Prostate cancer biomarkers |
| PCT/EP2018/055670 WO2018162596A1 (en) | 2017-03-07 | 2018-03-07 | Cancer biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3593139T3 true PL3593139T3 (pl) | 2025-11-17 |
Family
ID=61617014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18710027.6T PL3593139T3 (pl) | 2017-03-07 | 2018-03-07 | Biomarkery nowotworowe |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190391151A1 (pl) |
| EP (2) | EP4614153A3 (pl) |
| JP (2) | JP7377527B2 (pl) |
| CN (1) | CN110383070A (pl) |
| AU (2) | AU2018231421B2 (pl) |
| CA (1) | CA3050203A1 (pl) |
| PL (1) | PL3593139T3 (pl) |
| WO (1) | WO2018162596A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019253118B2 (en) | 2018-04-13 | 2024-02-22 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay of biological samples |
| US20200318174A1 (en) * | 2019-04-03 | 2020-10-08 | Agilent Technologies, Inc. | Compositions and methods for identifying and characterizing gene translocations, rearrangements and inversions |
| US20220333206A1 (en) * | 2019-07-29 | 2022-10-20 | Seoul National University Hospital | Biomarker for diagnosing pancreatic cancer, and use thereof |
| KR102699848B1 (ko) * | 2019-07-29 | 2024-08-29 | 서울대학교병원 | 암 진단을 위한 바이오마커 |
| CN110551819B (zh) * | 2019-08-23 | 2023-05-16 | 伯克利南京医学研究有限责任公司 | 一组卵巢癌预后相关基因的应用 |
| CA3216733A1 (en) * | 2021-04-28 | 2022-11-03 | Francesco Gatto | Cancer biomarkers |
| CN113740521A (zh) * | 2021-08-27 | 2021-12-03 | 安徽贝铭生物科技有限公司 | 检测尿液中癌胚硫酸软骨素的制剂在制备诊断泌尿系统恶性肿瘤的制剂、试剂盒中的应用 |
| CN117604112B (zh) * | 2024-01-23 | 2024-04-16 | 杭州华得森生物技术有限公司 | 用于胰腺癌诊断和预后判断的生物标志物及其应用 |
| CN119985978B (zh) * | 2025-01-19 | 2025-10-31 | 重庆医科大学 | Chpf2在胶质母细胞瘤中作用机制的研究方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9807045D0 (en) | 1998-04-01 | 1998-06-03 | Rudi Knut | Nucleic acid detection method |
| US8183003B2 (en) * | 2009-01-02 | 2012-05-22 | Zacharon Pharmaceuticals, Inc. | Polymer end group detection |
| US8592140B2 (en) * | 2009-01-02 | 2013-11-26 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
| US20120207753A1 (en) * | 2009-08-21 | 2012-08-16 | Centre Hospitalier Universitaire Vaudois | Methods of using cd44 fusion proteins to treat cancer |
| US8846034B2 (en) * | 2011-10-24 | 2014-09-30 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| ES2676029T3 (es) | 2012-02-09 | 2018-07-16 | Var2 Pharmaceuticals Aps | Direccionamiento de glicanos de sulfato de condroitina |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| CN108700567B (zh) | 2016-03-07 | 2022-05-10 | 爱丽卜塔有限公司 | 癌症生物标志物 |
-
2018
- 2018-03-07 EP EP25190997.4A patent/EP4614153A3/en active Pending
- 2018-03-07 JP JP2019548657A patent/JP7377527B2/ja active Active
- 2018-03-07 WO PCT/EP2018/055670 patent/WO2018162596A1/en not_active Ceased
- 2018-03-07 CA CA3050203A patent/CA3050203A1/en active Pending
- 2018-03-07 EP EP18710027.6A patent/EP3593139B1/en active Active
- 2018-03-07 AU AU2018231421A patent/AU2018231421B2/en active Active
- 2018-03-07 US US16/489,960 patent/US20190391151A1/en active Pending
- 2018-03-07 CN CN201880016407.XA patent/CN110383070A/zh active Pending
- 2018-03-07 PL PL18710027.6T patent/PL3593139T3/pl unknown
-
2023
- 2023-07-11 JP JP2023113458A patent/JP7640119B2/ja active Active
-
2024
- 2024-09-16 AU AU2024219766A patent/AU2024219766A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024219766A1 (en) | 2024-10-10 |
| CA3050203A1 (en) | 2018-09-13 |
| JP7377527B2 (ja) | 2023-11-10 |
| EP3593139A1 (en) | 2020-01-15 |
| JP2020511643A (ja) | 2020-04-16 |
| EP3593139C0 (en) | 2025-08-27 |
| US20190391151A1 (en) | 2019-12-26 |
| WO2018162596A1 (en) | 2018-09-13 |
| EP3593139B1 (en) | 2025-08-27 |
| AU2018231421A1 (en) | 2019-08-15 |
| CN110383070A (zh) | 2019-10-25 |
| EP4614153A3 (en) | 2025-12-03 |
| EP4614153A2 (en) | 2025-09-10 |
| JP2023133320A (ja) | 2023-09-22 |
| JP7640119B2 (ja) | 2025-03-05 |
| AU2018231421B2 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2566681B (en) | Biomarker | |
| PL3593139T3 (pl) | Biomarkery nowotworowe | |
| SG10202110526WA (en) | Biomarkers for cancer therapeutics | |
| GB201919219D0 (en) | Cancer biomarkers | |
| GB201614455D0 (en) | Biomarkers | |
| SG11201706223VA (en) | Biomarkers for pancreatic cancer | |
| GB201500584D0 (en) | Cancer biomarkers | |
| SG10202007262PA (en) | Copanlisib biomarkers | |
| SG10202007322PA (en) | Copanlisib biomarkers | |
| GB201703058D0 (en) | Biomarkers | |
| ZA202001821B (en) | Biomarker | |
| GB201710858D0 (en) | Biomarker | |
| GB201704267D0 (en) | Novel biomarker | |
| GB201814487D0 (en) | Cancer | |
| GB201800733D0 (en) | Cancer | |
| GB201703123D0 (en) | Biomarkers | |
| GB2546773B (en) | Cancer | |
| GB201512133D0 (en) | Biomarkers | |
| GB201817968D0 (en) | Cancer biomarkers | |
| GB201703641D0 (en) | Cancer biomarkers | |
| GB201807879D0 (en) | Cancer biomarkers | |
| GB201720776D0 (en) | Biomarkers | |
| GB201703640D0 (en) | Prostate cancer biomarkers | |
| GB201706669D0 (en) | Biomarkers | |
| GB201702986D0 (en) | Biomarkers |